Show simple item record

dc.contributor.advisorMcBride, Alien
dc.contributor.advisorAnwer, Faizen
dc.contributor.authorBerger, Garrett
dc.contributor.authorLawson, Stephanie
dc.contributor.authorRoyball, Kelsey
dc.date.accessioned2017-06-08T17:31:00Z
dc.date.available2017-06-08T17:31:00Z
dc.date.issued2017
dc.identifier.doihttps://doi.org/10.1016/j.critrevonc.2016.11.009
dc.identifier.urihttp://hdl.handle.net/10150/624029
dc.descriptionClass of 2017 Abstracten
dc.descriptionThis project is related to the article that was later published, available at this link: https://doi.org/10.1016/j.critrevonc.2016.11.009
dc.description.abstractObjectives: Brentuximab vedotin (BV) is an antibody-drug conjugate comprising a CD30-directed antibody conjugated to the microtubule-disrupting agent MMAE via a protease cleavable linker. BV is FDA approved for use in relapsed classical Hodgkin lymphoma and relapsed systemic Methods: primary study outcomes being objective response rate. PubMed (1946-2015), EMBASE (1947-2015), and Cochrane Central Register of Controlled Trials (1898-2015). Inclusion criteria included all studies and case reports of NHLs in which BV therapy was administered. Twenty-eight articles met these criteria. Results: Utilizing the twelve clinical subtypes, we found clinical evidence of BV and stratified the study populations into three groups: B-cell malignancies (group A), T-cell malignancies (group B), and non-B or non-T-cell hematological malignancies (group C). Across the group A malignancies, there were 87 patients. 48% experienced an objective response (OR). Across the group B malignancies, there were 274 patients. 74% experienced an OR. Across the group C malignancies, there were 9 patients. 44% experienced an OR. Conclusions: Our findings indicate that BV induces a variety of responses, largely positive and variable between NHL subtypes. With properly powered prospective studies, BV may prove to be a strong candidate in the treatment of CD30+ malignancies.
dc.language.isoen_USen
dc.publisherThe University of Arizona.en
dc.relation.urlhttps://doi.org/10.1016/j.critrevonc.2016.11.009
dc.rightsCopyright © is held by the author.en
dc.subjectNon-Hodgkin Lymphomaen
dc.subjectBrentuximab vedotinen
dc.subjectMalignanciesen
dc.subject.meshLymphoma, Non-Hodgkinen
dc.subject.meshBrentuximab Vedotinen
dc.subject.meshLymphoma, Large-Cell, Anaplasticen
dc.subject.meshNeoplasmsen
dc.titleBrentuximab Vedotin for Treatment of Non-Hodgkin Lymphomas: A Systematic Reviewen_US
dc.typetexten
dc.typeElectronic Reporten
dc.contributor.departmentCollege of Pharmacy, The University of Arizonaen
dc.description.collectioninformationThis item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.en
html.description.abstractObjectives: Brentuximab vedotin (BV) is an antibody-drug conjugate comprising a CD30-directed antibody conjugated to the microtubule-disrupting agent MMAE via a protease cleavable linker. BV is FDA approved for use in relapsed classical Hodgkin lymphoma and relapsed systemic Methods: primary study outcomes being objective response rate. PubMed (1946-2015), EMBASE (1947-2015), and Cochrane Central Register of Controlled Trials (1898-2015). Inclusion criteria included all studies and case reports of NHLs in which BV therapy was administered. Twenty-eight articles met these criteria. Results: Utilizing the twelve clinical subtypes, we found clinical evidence of BV and stratified the study populations into three groups: B-cell malignancies (group A), T-cell malignancies (group B), and non-B or non-T-cell hematological malignancies (group C). Across the group A malignancies, there were 87 patients. 48% experienced an objective response (OR). Across the group B malignancies, there were 274 patients. 74% experienced an OR. Across the group C malignancies, there were 9 patients. 44% experienced an OR. Conclusions: Our findings indicate that BV induces a variety of responses, largely positive and variable between NHL subtypes. With properly powered prospective studies, BV may prove to be a strong candidate in the treatment of CD30+ malignancies.


This item appears in the following Collection(s)

Show simple item record